Kamada Ltd. (KMDA) Stock Analysis & Investment Frameworks
Kamada Ltd. (KMDA) stock analysis on Invetso. Review Kamada Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Kamada Ltd. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: IL
Kamada Ltd. Key Financial Metrics
- Market Cap: $452.03M
- Revenue: $180.46M
- P/E Ratio: 22.39
- ROE: 8.37%
- ROIC: 6.90%
- Dividend Yield: 5.36%
About Kamada Ltd.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Kamada Ltd. Investment Frameworks
Invetso analyzes Kamada Ltd. (KMDA) across the following frameworks:
- Kamada Ltd. 10Y Growth Potential
- Kamada Ltd. Scenario Analysis
- Kamada Ltd. Risks & Opportunities
- Kamada Ltd. Economic Moat
- Kamada Ltd. Business Model
- Kamada Ltd. Management
- Kamada Ltd. SWOT Analysis
- Kamada Ltd. Porter's 5 Forces
- Kamada Ltd. PESTLE Analysis
- Kamada Ltd. ESG Analysis